LSE · KOO.L
Kooth plc
£1.90£0.00 (0.0%)
Kooth plc’s quoted price sits in the upper half of its reported 52-week range, 6.65% below the high.
Loading market information…
LSE · HEMO.L · GBp
Stock price, earnings
Quote as of Oct 29, 2026, 04:35 PM UTC. Cached market data; not a live quote.
One-year closing-price history · GBp. Historical prices are not a forecast.
Hemogenyx Pharmaceuticals Plc’s quoted price sits in the lower half of its reported 52-week range, 44.26% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Hemogenyx Pharmaceuticals Plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Hemogenyx Pharmaceuticals Plc is a preclinical biotechnology company dedicated to the discovery, advancement, and commercialization of innovative therapies for various blood diseases. The firm's pipeline is heavily focused on creating novel solutions for the bone marrow and hematopoietic stem cell (BM/HSC) transplant sector. Key developments include a CDX bi-specific antibody, engineered to target challenging conditions such as relapsed/refractory acute myeloid leukaemia (R/R AML), specific forms of acute lymphoblastic leukaemia, and myelodysplastic syndrome, aiming to replace traditional chemotherapy or radiation for transplant conditioning. Also under development is HEMO-CAR-T therapy, which utilizes chimeric antigen receptor T-cells to effectively identify and destroy human acute myeloid leukaemia cells in laboratory and in vivo settings. Additionally, the company is advancing Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapeutic specifically for BM/HSC transplant procedures. Founded in 2012, Hemogenyx Pharmaceuticals is headquartered in London, United Kingdom.
Latest available per-share figures in GBP. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:42 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
£1.90£0.00 (0.0%)
Kooth plc’s quoted price sits in the upper half of its reported 52-week range, 6.65% below the high.
£0.10+£0.00 (+2.63%)
Ondine Biomedical Inc.’s quoted price sits in the upper half of its reported 52-week range, 37.1% below the high.
£0.11+£0.00 (+1.11%)
Creo Medical Limited’s quoted price sits in the lower half of its reported 52-week range, 38.51% below the high.
£0.07-£0.00 (-2.26%)
Poolbeg Pharma PLC’s quoted price sits in the upper half of its reported 52-week range, 32.64% below the high.
£0.06+£0.00 (+8.11%)
hVIVO plc’s quoted price sits in the lower half of its reported 52-week range, 45.45% below the high.
£0.83£0.00 (0.0%)
Arecor Therapeutics plc’s quoted price sits in the upper half of its reported 52-week range, 13.16% below the high.
£0.04+£0.00 (+6.12%)
ImmuPharma PLC’s quoted price sits in the lower half of its reported 52-week range, 67.09% below the high.
£0.15-£0.01 (-7.58%)
Sareum Holdings plc’s quoted price sits in the lower half of its reported 52-week range, 61.88% below the high.
